PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 93 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $5,866,626 | +149.5% | 169,311 | +108.3% | 0.00% | – |
Q1 2024 | $2,351,141 | +40.6% | 81,270 | +11.4% | 0.00% | – |
Q4 2023 | $1,672,307 | +160.4% | 72,931 | +89.4% | 0.00% | – |
Q3 2023 | $642,280 | +6.6% | 38,506 | +76.6% | 0.00% | – |
Q2 2023 | $602,365 | -53.4% | 21,809 | -61.2% | 0.00% | -100.0% |
Q1 2023 | $1,292,968 | +112.0% | 56,216 | +0.6% | 0.00% | – |
Q4 2022 | $609,770 | +600.9% | 55,891 | +443.2% | 0.00% | – |
Q3 2022 | $87,000 | -71.0% | 10,289 | -72.9% | 0.00% | – |
Q2 2022 | $300,000 | -58.7% | 37,956 | +23.6% | 0.00% | – |
Q1 2022 | $727,000 | -81.5% | 30,700 | -73.2% | 0.00% | -100.0% |
Q4 2021 | $3,922,000 | +282.6% | 114,696 | +98.3% | 0.00% | – |
Q3 2021 | $1,025,000 | +251.0% | 57,854 | +299.7% | 0.00% | – |
Q4 2020 | $292,000 | +12.7% | 14,473 | +9.1% | 0.00% | – |
Q3 2020 | $259,000 | +197.7% | 13,268 | +2.5% | 0.00% | – |
Q2 2018 | $87,000 | -62.5% | 12,945 | +18.1% | 0.00% | -100.0% |
Q3 2016 | $232,000 | – | 10,964 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Johnson & Johnson Innovation - JJDC, Inc. | 2,449,183 | $43,253,000 | 8.50% |
BVF INC/IL | 2,367,288 | $41,806,000 | 2.58% |
RTW INVESTMENTS, LP | 3,383,208 | $59,747,000 | 1.68% |
Novo Holdings A/S | 824,169 | $14,555,000 | 0.94% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,013,495 | $17,898,000 | 0.52% |
Sofinnova Investments, Inc. | 326,064 | $5,758,000 | 0.36% |
FARALLON CAPITAL MANAGEMENT LLC | 2,500,000 | $44,150,000 | 0.35% |
Virtus ETF Advisers LLC | 21,639 | $382,000 | 0.18% |
Baker Brothers Advisors | 1,911,446 | $33,756,000 | 0.15% |
King Wealth Management Group | 22,000 | $389,000 | 0.11% |